Onychomycosis Clinical Trial
— MYCDERMOfficial title:
Pilot Study on the Evaluation of the Efficacy, Tolerability and Safety of Topical and Oral Antifungals in the Treatment of Onychomycosis and Creation of a Library of Dermatological Clinical Isolates
Verified date | May 2024 |
Source | University of Rome Tor Vergata |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
This pilot, prospective, observational drug study aims to evaluate the efficacy, tolerability and safety of topical and oral antifungals in the treatment of onychomycosis caused by yeasts, dermatophytic moulds and non-dermatophytic moulds as well as correlate the scores in the MALDI-TOF method for the 'identification of genus and species of higher fungi utilizing the comparison between identification in direct optical microscopy, culture examination and optical microscopy and macroscopic and onychoscopic clinical aspects. Furthermore, an optional substudy will evaluate the drug resistance of clinical isolates using molecular or genetic methods.
Status | Active, not recruiting |
Enrollment | 200 |
Est. completion date | December 25, 2025 |
Est. primary completion date | July 20, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - patients with clinical suspicion of onychomycosis. Exclusion Criteria: - Patients deemed unsuitable by the investigator - Patients with documented sensitivity to study drugs such as azoles, allylamine, and ciclopirox olamine. - Failure to adhere to topical or oral therapy; - Replacement of the therapy reported in the study protocol; - Voluntary decision by the patient |
Country | Name | City | State |
---|---|---|---|
Italy | Tor Vergata Univerisity Hospital | Rome |
Lead Sponsor | Collaborator |
---|---|
University of Rome Tor Vergata |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Rate of correct classification by the test (MALDI-TOF MS profiling) from positive cultures | For each culture positive clinical sample, the status ("correct" or "incorrect") of the classification of the sample ("infected" or "not infected") by the test (MALDI-TOF MS profiling) will be determined. Then the rate of correct classification will be calculated. The test will be considered efficient when it has reached a correct classification rate of more than 95%. | Week 0 | |
Other | Rate of correct classification by KOH Test from clinical isolates | For each clinical sample, the status ("correct" or "incorrect") of the classification of the sample ("infected" or "not infected") by the KOH test will be determined. Then the rate of correct classification will be calculated. The test will be considered efficient when it has reached a correct classification rate of more than 95%. | Week 0 | |
Other | Rate of correct classification by direct Microscopy Test from positive cultures | For each culture positive clinical sample, the status ("correct" or "incorrect") of the classification of the sample ("infected" or "not infected") by the test (Microscopy of the cultures) will be determined. Then the rate of correct classification will be calculated. The test will be considered efficient when it has reached a correct classification rate of more than 95%. | Week 0 | |
Other | Correlation between the identified fungi pathogens and the clinical course of the participants. | In fungi infected participants, the presence of a correlation between the presence of fungal infection and the clinical evolution of patients will be determined. | Week 52 | |
Primary | Change of Onychomycosis Severity Index (OSI) | Change of Onychomycosis Severity Index (OSI) from baseline to 12 months:
Area of Involvement (0-5 points) Proximity of Disease to Matrix (1-5 points) Presence of Dermatophytoma or Subungual Hyperkeratosis 2 mm ( 0 or 10 points) |
week 0,12,24,36,52 | |
Primary | Safety and Tolerability: Established from patient incidence of Treatment-Emergent Adverse Events | Indicated by the number of patients with treatment-related adverse events assessed by Common Terminology Criteria for Adverse Events (CTCAE). | Monitored from screening visit to end of study visit (52 week) | |
Primary | Complete Cure at 12 months in the Target Toes | Complete Cure is defined as 1) 100% healthy, clear nail, and 2) negative mycology. Healthy, clear nail is absent any disease involvement attributable to DLSO and is determined by Investigator Global Assessment (IGA). Negative mycology is defined as zero visualization of septate hyphae by KOH microscopy (negative KOH) combined with a fungal culture negative for causal dermatophytes (negative fungal culture). | Week 52 | |
Secondary | Change in Dermatology life Quality Index (DLQI) | Evaluation of the quality of life of treated patients before and after treatment (0-30 points) | week 0,12,24,36,52 | |
Secondary | Patient Global Assessment | To establish each patient's impression of DLSO improvement in their target toe over the study period, patients will reference the following scale (0 = clear of DLSO, 1 = marked improvement of DLSO, 2 = moderately improved DLSO, 3 = slightly improved DLSO, 4 = unchanged, 5 = worse) | week 0,12,24,36,52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03098615 -
Study Evaluating the Effect of Jublia on Dermatophytomas
|
Phase 4 | |
Recruiting |
NCT01666002 -
Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
|
N/A | |
Terminated |
NCT01208168 -
Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
|
Phase 3 | |
Terminated |
NCT01208129 -
Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
|
Phase 3 | |
Completed |
NCT01180491 -
A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis
|
N/A | |
Completed |
NCT00385502 -
A Trial of the Safety and Efficacy of EcoNailâ„¢ in the Treatment of Fungus Infections of the Great Toenail
|
Phase 2 | |
Completed |
NCT00253305 -
Topical Gel Anti-Fungal Agent for Tinea Unguium
|
Phase 2 | |
Not yet recruiting |
NCT05809297 -
Diode Laser and Photodynamic Therapy Vs. Ciclopirox.
|
Phase 4 | |
Completed |
NCT03405818 -
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
|
Phase 4 | |
Completed |
NCT02588599 -
A Retrospective Analysis of the Effects of Low Level Laser Therapy on Toenail Onychomycosis
|
N/A | |
Recruiting |
NCT02436291 -
Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis
|
Phase 4 | |
Completed |
NCT01851590 -
Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis
|
Phase 4 | |
Completed |
NCT01452490 -
Diode Laser Treatment of Onychomycosis
|
N/A | |
Withdrawn |
NCT00938925 -
Effectiveness of Podiatry Care on Onychomycosis (EPOCAON)
|
N/A | |
Recruiting |
NCT00808366 -
Efficacy and Safety of RV4104A Ointment in Onychomycosis
|
N/A | |
Completed |
NCT00768768 -
Iontophoretic Application of Terbinafine Gel to the Large Toe Nail
|
Phase 1 | |
Completed |
NCT00781820 -
Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste
|
Phase 3 | |
Completed |
NCT00777868 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis
|
Phase 2 | |
Recruiting |
NCT06074315 -
Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis
|
N/A | |
Completed |
NCT01039883 -
A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule
|
Phase 1 |